Between-meal risedronate does not alter bone turnover in nursing home residents
Between-meal risedronate does not alter bone turnover in nursing home residents
复制标题
DOI：
10.1111/j.1532-5415.2006.00696.x
复制
发表时间：
2006-05-01
影响因子：
6.3
通讯作者：
Binkley, NC
中科院分区：
文献类型：
--
作者：
Agrawal, S;Krueger, DC;Binkley, NC
目的：评价每周一次餐间利塞膦酸盐与每日钙630 mg和维生素D 400IU对骨转换标志物的影响。设计：随机、双盲、安慰剂对照试验。设置：熟练疗养院(NH)。对象：60名技术熟练的NH居民(男性46人，女性14人)，平均年龄+/-6岁，随机分为利塞膦酸盐30 mg(n=31)或匹配的安慰剂(n=29)，每周一次，共12周。结果：治疗前、治疗6周和12周时，利塞膦酸对骨碱性磷酸酶(BSAP)、1型胶原N-端肽(NTX)、25-羟基维生素D(25OHD)和甲状旁腺激素的影响均显著高于安慰剂组(P<0.05)。
OBJECTIVES: To assess the effect of between-meal weekly risedronate and daily calcium 630 mg and vitamin D 400 IU on bone turnover markers.DESIGN: Randomized, double-blind, placebo-controlled trial.SETTING: Skilled nursing home (NH).PARTICIPANTS: Sixty skilled-NH residents (46 men, 14 women), mean age +/- standard deviation of 76 +/- 6, were randomized to receive risedronate 30 mg (n = 31) or matching placebo (n = 29) once weekly for 12 weeks. All received 315 mg calcium with 200 IU vitamin D twice daily.MEASUREMENTS: Bone-specific alkaline phosphatase (BSAP), N-telopeptide of type 1 collagen (NTx), 25-hydroxy-vitamin D (25OHD), and parathyroid hormone were measured at baseline and 6 and 12 weeks.RESULTS: Risedronate reduced BSAP significantly more than placebo (P